ArticleFuture science OA2025
Biomarker urinary neutrophil gelatinase-associated lipocalin as a predictor of acute kidney injury in neonates.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a predictive biomarker for Acute Kidney Injury (AKI) in neonates undergoing gastrointestinal surgery. MATERIALS &
methodsA prospective cohort study included 45 neonates with gastrointestinal congenital malformations who underwent abdominal surgery within the first 28 days of life at two pediatric centers in Almaty, Kazakhstan. AKI was diagnosed using modified neonatal KDIGO criteria, dividing neonates into AKI[+] and AKI[-] groups. uNGAL levels were measured pre-surgery and on postoperative days 1, 3, and 7. Statistical analysis, including ROC curve analysis, was performed using SPSS to evaluate uNGAL's sensitivity and specificity as a biomarker.
resultsAKI was diagnosed in 42.2% of neonates. Pre-surgery uNGAL levels were significantly higher in the AKI group (184.4 ng/ml vs. 56.5 ng/ml). Post-surgery, uNGAL peaked at 493.9 ng/ml on day 1, with sensitivities of 89.5% and 94.7% on days 1 and 7. Specificity was highest on days 1 and 3 (96.2% and 100%). The mortality rate among AKI-affected neonates was 31.5%.
conclusionuNGAL is a sensitive and specific biomarker for early AKI detection in neonates post-gastrointestinal surgery, enabling timely interventions and potentially reducing mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.